葡萄膜炎：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 中國葡萄膜炎市場預計將從 2025 年的約 8,070 萬美元成長到 2035 年的近 9,730 萬美元，呈現逐步擴張的態勢。
• 以下因素正在推動市場成長：
• 生物製藥和非類固醇免疫調節療法的廣泛應用
• 改善慢性病和復發性疾病的診斷和長期管理
• 市場規模的擴大是由治療週期延長和先進眼科治療方法的日益普及所推動的。
• 未來市場成長將取決於標靶免疫療法的發展、更安全的長期治療策略以及難治性葡萄膜炎治療的改善。

葡萄膜炎：新興治療方法和TPP的見解

Thelansis 的「葡萄膜炎：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026」對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

葡萄膜炎概述

葡萄膜炎是一組涉及葡萄膜系統的異質性眼內發炎性疾病，葡萄膜系統由虹膜、睫狀體和脈絡膜組成。從解剖學角度來看，葡萄膜炎可分為前葡萄膜炎、中間葡萄膜炎、後葡萄膜炎和全葡萄膜炎，其中前葡萄膜炎最常見。其病理生理機轉包括皰疹病毒、弓漿蟲病、結核病和梅毒等感染因素，以及非感染性的免疫介導機轉。後者常與HLA-B27相關性脊椎關節病變、類肉瘤病、白塞氏症、幼年特發性關節炎、多發性硬化症等全身性疾病有關。患者可能出現眼痛、眼紅、畏光、視物模糊和飛蚊症等症狀，具體症狀因病變部位而異。另一方面，慢性或後葡萄膜炎可逐漸進展，並可能透過白內障、青光眼、囊性黃斑部水腫和視網膜剝離威脅視力。診斷需要結合裂隙燈顯微鏡檢查、散瞳眼底檢查、光學同調斷層掃描(OCT) 和螢光造影，以及感染或自體免疫病因的全身性檢查。非感染性疾病的治療基石仍是皮質類固醇（局部、眼眶周圍或全身用藥），而對於慢性或復發性疾病，則使用非類固醇類免疫調節劑，例如胺基甲基葉酸、黴酚酸酯和Azathioprine。對於難治性病例，則使用生物製藥，特別是Adalimumab，這是一種專門核准用於治療非感染性葡萄膜炎的抗TNF藥物。預後取決於病因、解剖位置和治療反應。多學科協作、定期眼科後續觀察和患者教育對於維持視力和生活品質至關重要。

主要亮點

• 預計到 2025 年，中國葡萄膜炎患者總數將約為 3,611,621 人，到 2035 年將增加至近 3,754,973 人，反映出疾病負擔日益加重。
• 在所有被診斷出患有此病的患者中，前葡萄膜炎仍然是最常見的臨床亞型。
• 慢性及復發性發炎仍然是長期視力障礙和生活品質下降的主要原因。
• 免疫抑制療法和生物製藥的廣泛應用正在改善難治性非感染性葡萄膜炎的治療。
• 早期診斷和多學科疾病管理對於預防不可逆的眼部併發症仍然至關重要。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 大公司
• 主要作用機制
• 發布日期預測等。
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 主要未滿足需求得到滿足的程度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Uveitis Disease Emerging Therapy and TPP Insights

Thelansis's "Uveitis Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Uveitis Disease Overview

Uveitis is a heterogeneous group of intraocular inflammatory disorders affecting the uveal tract - iris, ciliary body, and choroid - classified anatomically as anterior, intermediate, posterior, or panuveitis, with anterior uveitis representing the most prevalent form. The pathophysiology encompasses both infectious triggers - including herpesviruses, toxoplasma, tuberculosis, and syphilis - and non-infectious immune-mediated mechanisms, the latter frequently associated with systemic conditions including HLA-B27-associated spondyloarthropathies, sarcoidosis, Behcet disease, juvenile idiopathic arthritis, and multiple sclerosis. Patients present with painful red eye, photophobia, blurred vision, and floaters - symptoms varying with anatomical location - while chronic or posterior uveitis may progress insidiously, threatening vision through cataract, glaucoma, cystoid macular oedema, and retinal detachment. Diagnosis integrates slit-lamp biomicroscopy, dilated fundoscopy, optical coherence tomography, fluorescein angiography, and targeted systemic workup to identify infectious or autoimmune aetiology. Corticosteroids - topical, periocular, or systemic - remain the therapeutic cornerstone for non-infectious disease, with steroid-sparing immunomodulators including methotrexate, mycophenolate, and azathioprine employed for chronic or recurrent disease. Biologics - particularly anti-TNF agents adalimumab, approved specifically for non-infectious uveitis - are utilised in refractory cases. Prognosis varies with aetiology, anatomical location, and treatment response; multidisciplinary collaboration, regular ophthalmological monitoring, and patient education are essential to preserving vision and quality of life.

Key Highlights

• In China, total prevalent uveitis cases are projected to increase from approximately 3,611,621 in 2025 to nearly 3,754,973 by 2035, reflecting a growing disease burden.
• Anterior uveitis remains the most common clinical subtype across diagnosed patient populations.
• Chronic and recurrent inflammation continues to contribute significantly to long-term visual impairment and reduced quality of life.
• Increasing use of immunosuppressive therapies and biologics is improving disease control in refractory non-infectious uveitis.
• Early diagnosis and multidisciplinary disease management remain critical to preventing irreversible ocular complications.

Market Overview

• The China uveitis market is projected to grow from approximately $80.70 MN in 2025 to nearly $97.30 MN by 2035, reflecting moderate market expansion.
• Market growth is supported by:
• Increasing adoption of biologics and steroid-sparing immunomodulatory therapies
• Improved diagnosis and long-term management of chronic and recurrent disease
• Market value growth is driven by rising treatment duration and increasing utilization of advanced ophthalmic therapies.
• Future market growth will depend on development of targeted immunotherapies, safer long-term treatment strategies, and improved management of refractory uveitis.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)